Lifecore Biomedical, Inc.
NASDAQ:LFCRDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $242.60M
- Beta
- 1.07
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$0.91
Volume 0.15M
Average 0.29M
LFCR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Lifecore Biomedical, Inc.NASDAQ: LFCR
EBITDA · Q3 FY2026 · quarter ended Mar 2026
EBITDA of -$5.28M in Q3 FY2026
Q3 FY2026 EBITDA was -$5.28M. Trailing-twelve-month EBITDA was -$1.03M.
Context
- EBITDA amounted to 6.8% of revenue in FY2025, down 20.9 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$95.31K (+98.9%) for the fiscal year ending May 2026, a step up from the -124.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.28M-204.4% QoQ
- Last fiscal yearMay 2025
- -$8.81M-124.8% YoY
- LTMMar 2026
- -$1.03M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -124.8% | +98.9% | +223.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (8.81M) USD
- Year-over-year change
- -124.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-25 | (8.81M) | -124.8% |
| FY2024 | 2024-05-26 | 35.6M | +207.3% |
| FY2023 | 2023-05-28 | (33.17M) | -358.3% |
| FY2022 | 2022-05-29 | 12.84M | +1401.3% |
| FY2021 | 2021-05-31 | (987K) | — |
EBITDA vs competitors
How LFCR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- EBITDA amounts to 0.8% of revenue for LFCR, versus a peer median of 71.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$10.48M CAD | -79.6% | — | 3.4% | |
| LTM Mar 2026 | -$1.03M USD | — | — | 0.8% | |
| LTM Mar 2026 | -$9.96M USD | +38.2% | — | 23.8% | |
| LTM Mar 2026 | -$31.68M USD | +27.7% | — | 39.8% | |
| LTM Mar 2026 | -€42.88M EUR | -67.7% | — | 319.0% | |
| LTM Mar 2026 | -$45.97M USD | -0.0% | — | 77.8% | |
| LTM Mar 2026 | -$50.86M USD | -14.6% | — | — | |
| FY2025 | -A$62.88M AUD | -41.2% | — | 1246.6% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.21M USD | -28.4% | — | 864.8% |
| LTM Mar 2026 | -CA$205.34M CAD | +57.2% | — | 65.7% | |
| Peer median (excluding LFCR) | — | -14.6% | — | 71.8% | |
Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Revenue | 100.87M | 111.27M | 103.27M | 128.26M | 128.87M |
| Cost of Revenue | 61.94M | 72.2M | 75.28M | 86.41M | 88.57M |
| Gross Profit | 38.94M | 39.07M | 27.99M | 41.85M | 40.3M |
| Gross Margin | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% |
| Research & Development | 6.68M | 7.84M | 8.74M | 8.58M | 8.26M |
| Selling, General & Admin | 27.72M | 34.66M | 38.97M | 40.46M | 44.05M |
| Operating Expenses | 47.76M | 50.86M | 49.78M | 50.69M | 57.54M |
| Depreciation & Amortization | 19.87M | 18.06M | 13.18M | 8M | 8.03M |
| EBITDA | (987K) | 12.84M | (33.17M) | 35.6M | (8.81M) |
| EBITDA Margin | -1.0% | 11.5% | -32.1% | 27.8% | -6.8% |
| Operating Income | (8.82M) | (11.79M) | (21.8M) | (8.84M) | (17.25M) |
| Operating Margin | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% |
| Interest Income | 48K | 81K | 68K | 0 | 0 |
| Interest Expense | 8.93M | 15.55M | 17.65M | 18.09M | 21.84M |
| Other Income / Expenses | (20.96M) | (8.9M) | (42.13M) | 18.36M | (21.43M) |
| Income Before Tax | (29.79M) | (20.69M) | (63.93M) | 9.51M | (38.67M) |
| Pre-Tax Margin | -29.5% | -18.6% | -61.9% | 7.4% | -30.0% |
| Income Tax Expense | (6.35M) | (5.21M) | 308K | 183K | 43K |
| Net Income | (32.29M) | (116.72M) | (99.56M) | 12.01M | (38.72M) |
| Net Margin | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% |
| EPS (Basic) | (1.12) | (3.97) | (3.32) | 0.39 | (1.27) |
| EPS (Diluted) | (1.12) | (3.97) | (3.32) | 0.33 | (1.27) |
| Weighted Avg Shares | 29.29M | 29.47M | 29.96M | 30.47M | 34.82M |
| Weighted Avg Shares (Diluted) | 29.29M | 29.47M | 29.96M | 36.66M | 34.82M |
Lifecore Biomedical, Inc.
NASDAQ:LFCR
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.